# CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

> **NCT03517176** · PHASE1 · COMPLETED · sponsor: **Lisata Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** CEND-1
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03517176
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-31
- **Primary completion:** 2020-06-19
- **Final completion:** 2020-06-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517176, "CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03517176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*